Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections

Effects of Carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients

(2014) Aziz Ogutlu et al.   Annals of Clinical Microbiology and Antimicrobials

Editorial Commentary: Rifampicin Plus Colistin in the Era of Extensively Drug-Resistant Acinetobacter baumannii Infections

(2013) T. P. Gauthier   CLINICAL INFECTIOUS DISEASES

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

(2013) Emanuele Durante-Mangoni et al.   CLINICAL INFECTIOUS DISEASES

Is there really no benefit to combination therapy with colistin?

(2013) Jason M Pogue et al.   Expert Review of Anti-Infective Therapy

Evaluation of Colistin-Ampicillin/Sulbactam Combination Efficacy in Imipenem-Resistant Acinetobacter baumannii Strains

(2013) Aytekin ÇIKMAN et al.   MIKROBIYOLOJI BULTENI

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia

(2012) S.-C. Kuo et al.   CLINICAL MICROBIOLOGY AND INFECTION

In vitroeffects of sulbactam combinations with different antibiotic groups against clinicalAcinetobacter baumanniiisolates

(2012) Aydin Deveci et al.   JOURNAL OF CHEMOTHERAPY

Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia: Impact of Appropriate Antimicrobial Therapy

(2012) Youn Jeong Kim et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Prediction of Patient Outcome from Acinetobacter baumannii Bacteremia with Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II Scores

(2011) Su-Jung Chen et al.   INTERNAL MEDICINE

Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections

(2011) J. Y. Song et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Renal and neurological side effects of colistin in critically ill patients

(2011) Herbert Spapen et al.   Annals of Intensive Care

Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients

(2010) Argyris Michalopoulos et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections

(2009) Ayşe Erbay et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

(2009) Matthew E. Falagas et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In vitro synergistic activity of tigecycline and colistin against XDR-Acinetobacter baumannii

(2009) Murat Dizbay et al.   JOURNAL OF ANTIBIOTICS

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii

(2009) Luigi Principe et al.   Annals of Clinical Microbiology and Antimicrobials

CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting

(2008) Teresa C. Horan et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Therapeutic options forAcinetobacter baumanniiinfections

(2008) Jordi Vila et al.   EXPERT OPINION ON PHARMACOTHERAPY